ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA. The poster presentation will provide efficacy, safety, pharmacodynamics and dose selection data on the novel γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of patients with newly diagnosed AML.
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual MeetingImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of CancerImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
ImCheck Appoints Stephan Braun as Chief Medical OfficerImCheck Appoints Stephan Braun as Chief Medical Officer
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual MeetingImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
ImCheck Appoints Thomas Civik as Independent Chairman of the BoardImCheck Appoints Thomas Civik as Independent Chairman of the Board
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACRImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual MeetingLow-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors
